Cargando…

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials

OBJECTIVES: Fluoropyrimidine-based regimens have been investigated as the second line chemotherapy in patients with advanced pancreatic cancer refractory to gemcitabine. We conducted this systematic review and meta-analysis to evaluate the efficacy and safety profile of fluoropyrimidine combination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Wei, Zhang, Lina, Liu, Xiao, Ma, Xiao, Wang, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980826/ https://www.ncbi.nlm.nih.gov/pubmed/36862702 http://dx.doi.org/10.1371/journal.pone.0282360

Ejemplares similares

Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis
por: Yang, Yong-Feng, et al.
Publicado: (2015)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017)

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
por: Wu, Lili, et al.
Publicado: (2021)

A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
por: Deac, Andrada-Larisa, et al.
Publicado: (2020)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Ginseng-containing traditional medicine preparations in combination with fluoropyrimidine-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis
por: Hu, Jiaqi, et al.
Publicado: (2023)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis
por: Marchetti, S, et al.
Publicado: (2001)

A narrative review of genetic factors affecting fluoropyrimidine toxicity
por: Gmeiner, William H.
Publicado: (2021)

Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
por: Katsumata, N., et al.
Publicado: (2011)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma
por: Itashiki, Yasutaka, et al.
Publicado: (2021)

Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis
por: Lu, Yajie, et al.
Publicado: (2022)

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Kataria, Satya Pal, et al.
Publicado: (2022)

Efficacy of Chinese herbal injections combined with fluoropyrimidine and oxaliplatin-based chemotherapy for advanced colorectal cancer: A protocol for systematic review and meta-analysis of randomized controlled trials
por: Wang, Shuo, et al.
Publicado: (2020)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
por: Wu, Fengpeng, et al.
Publicado: (2021)

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer
por: Leonard, R C F
Publicado: (2001)

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation
por: Milano, G, et al.
Publicado: (2004)

In vivo Antitumor Effects of Fluoropyrimidines on Colon Adenocarcinoma 38 and Enhancement by Leucovorin
por: Iigo, Masaaki, et al.
Publicado: (1992)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

DPD status and fluoropyrimidines-based treatment: high activity matters too
por: Chamorey, Emmanuel, et al.
Publicado: (2020)

The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease
por: Fabin, Natalia, et al.
Publicado: (2022)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
por: Merloni, Filippo, et al.
Publicado: (2019)

Rechallenging Fluoropyrimidine-Induced Cardiotoxicity and Neurotoxicity: A Report of Two Cases
por: Ashish, Sethi, et al.
Publicado: (2022)

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
por: Yamanaka, T, et al.
Publicado: (2007)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009)

Effectiveness and Safety of Chinese Herbal Injections Combined with Fluoropyrimidine and Oxaliplatin-based Chemotherapy for Advanced Colorectal Cancer: A Systematic Review and Meta-analysis of 63 Randomized Controlled Trials
por: Wang, Shuo, et al.
Publicado: (2021)

Relevance of MTHFR polymorphisms with response to fluoropyrimidine-based chemotherapy in oesophagogastric cancer: a meta-analysis
por: Zhong, Lei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_at5mng7569qaabgptt0eqhv1re